Inhibiting the transient receptor potential A1 ion channel
View Patent ↗This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein,
R 1 is hydrogen or —CH 2 —R 1a , wherein R 1a is a phosphate moiety;
R 2 is CH 3 ;
R 3 is CH 3 ; and
A is N or CH.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) is a compound of Formula (Ia)
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is CH.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is N.
5. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein,
R 1 is hydrogen or —CH 2 —R 1a , wherein R 1a is a phosphate moiety;
R 2 is hydrogen;
R 3 is CH 3 ; and
A is N.
6. A compound selected from:
(S)-2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-(2,2-dimethylpyrrolidin-1-yl)pyrimidin-5-yl)pyrazin-2-yl)propanamide,
(S)-2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-((S)-2-methylpyrrolidin-1-yl)pyrimidin-5-yl)pyrazin-2-yl)propanamide,
or a pharmaceutically acceptable salt thereof.
7. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein,
R 1 is hydrogen or —CH 2 —R 1a , wherein R 1a is a phosphate moiety;
R 2 is hydrogen;
R 3 is CH 3 ; and
A is CH.
8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen.